MORRIS PLAINS, N.J., Nov. 16, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 7 presentations involving 4 of its product candidates have been accepted for presentation at the 53rd American Society of Hematology (ASH) Annual Meeting, scheduled for December 10 – 13, 2011, in San Diego, CA. The abstracts include oral and poster presentations across a spectrum of hematologic malignancies and autoimmune disease. The schedule and meeting places for the presentations, together with the publication numbers, are listed below:
-
"Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2." [Publication No. 573, Oral Session: Acute Lymphoblastic Leukemia – Therapy, excluding Transplantation: Biological Strategies. Monday, December 12, 3:15 pm, Room 29, San Diego Convention Center]
-
"Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL)." [Publication No. 599, Oral Session: Lymphoma – Preclinical – Chemotherapy and Biologic Agents: Novel targeted therapy of B-cell malignancies. Monday, December 12, 3:45 pm, Room 31, San Diego Convention Center]
-
"FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death." [Publication No. 600, Oral Session: Lymphoma – Preclinical – Chemotherapy and Biologic Agents: Novel targeted therapy of B-cell malignancies. Monday, December 12, 4:00 pm, Room 31, San Diego Convention Center]
-
"Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo." [Publication No. 1796, Poster Session: CLL – Therapy, excluding Transplantation: Poster I. Saturday, December 10, 5:30 pm – 7:30 pm, Hall GH, San Diego Convention Center]
-
"Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia." [Publication No. 3302, Poster Session: Disorders of Platelet Number or Function: Poster III. Monday, December 12, 6:00 pm – 8:00 pm, Hall GH, San Diego Convention Center]
-
"Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma." [Publication No. 3707, Poster Session: Lymphoma – Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III. Monday, December 12, 6:00 pm – 8:00 pm, Hall GH, San Diego Convention Center]
- "Combination Therapy with FTY720 (Fingolimod) and Bispecific Anti-CD20/CD74 Antibodies in Mantle Cell Lymphoma." [Publication No. 3736, Poster Session: Lymphoma – Pre-Clinical – Chemotherapy and Biologic Agents: Poster III. Monday, December 12, 6:00 pm – 8:00 pm, Hall GH, San Diego Convention Center]
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 183 patents issued in the United States and more than 400 foreign patents, protects our product candidates and technologies. For additional information on us, please visit our website at http://www.immunomedics.com/">www.immunomedics.com. The information on our website does not, however, form a part of this press release.
This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.